A total of 1,07,77,284 COVID-19 cases have been reported in India till February 3, the second highest in absolute numbers after the US, the government told Lok Sabha on Friday, underlining that the country is witnessing a sustained decline in the number of infections reported daily since the reported peak in mid-September 2020.
"Although high in absolute terms, India has managed to restrict the morbidity to 7,801 cases per million population, which is far lower than other similarly affected countries," Minister of State for Health Ashwini Choubey said in a written reply.
Six states- Kerala (43.37 per cent), Maharashtra (26.76), Karnataka (3.71), West Bengal (3.31), Uttar Pradesh (3.13) and Tamil Nadu (2.82 per cent) --account for 83 per cent of all active cases in the country.
"Since the reported peak in mid-September 2020, India is witnessing a sustained decline in the number of cases reported daily. However, resurgence of COVID-19 cases has been reported from a number of countries in Europe and Americas, therefore continuous monitoring of the evolving situation is being undertaken at all level, to pick up on the earliest signs of resurgence and issue necessary existing SOPs/Advisories accordingly," the minister said.
Further, the government continues to focus on intensive risk communication to limit viral transmission by advocating adherence to COVID appropriate behaviours (wearing of mask/face covers; physical distancing and hand hygiene), he said.
Additionally, the government has rolled out COVID-19 vaccination since January 16 and till February 3, 41,38,918 people have been inoculated.
Responding to a question on the number of people found positive with the new UK strain of COVID-19 in the country and the effect of new Covishield and Covaxin vaccines therefor, Choubey said a surveillance system has been put in place to identify this variant among those with travel history to the UK from December 23.
Till February 1, 147 travelers and their contacts have been tested positive for UK strain in India.
"At present there is no evidence to suggest that current vaccines (Covishield and Covaxin) will fail to protect against COVID-19 variants reported from the United Kingdom," Choubey underscored.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)